Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group

Purpose: Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice. Methods/patients: Retrospective, multicenter study promoted by the Thrombosis and Cancer S...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez Cánovas, M., Fernández Garay, D., Adoamnei, E., Guirao García, E., López Robles, J., Cacho Lavin, D., Martínez de Castro, E., Campos Balea, Begoña, Garrido Fernandez, Alberto, Fernández Pérez, Isaura, Ferrández Arias, A., Suarez, N., Quintanar Verduguez, T., Lobo de Mena, M., Rodríguez, L., Gutierrez, D., Martín Fernández de Soiginie, A.M., García Adrián, S., Ferrer Pérez, A.I., Delgado Heredia, M.J., Muñoz Lerma, A., Luque, R., Mazariegos Rubí, M., Rúperez Blanco, A.B., García Escobar, I., Mendiola, J., Muñoz Martín, A.J.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21593
Acceso en línea:https://portalcientifico.sergas.gal//documentos/6444edf248c3090deaa26376
http://hdl.handle.net/20.500.11940/21593
Access Level:acceso abierto
Palabra clave:Humans
Immune Checkpoint Inhibitors
Venous Thromboembolism
Retrospective Studies
Urinary Bladder
Thrombosis
Medical Oncology
Carcinoma, Renal Cell
Kidney Neoplasms
Urinary Bladder Neoplasms
Serum Albumin
Risk Factors
AS Lugo
CHULA
AS Vigo
CHUVI
Descripción
Sumario:Purpose: Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of information apropos patients in routine clinical practice. Methods/patients: Retrospective, multicenter study promoted by the Thrombosis and Cancer Section of the Spanish Society of Medical Oncology (SEOM). Individuals with kidney or bladder cancer who initiated ICI between 01/01/2015 and 12/31/2020 were recruited. Minimum follow-up was 6 months (except in cases of demise). The primary objective was to calculate the incidence of ICI-associated VTE/AT and secondary objectives included to analyze their impact on survival and identify variables predictive of VTE/AT. Results: 210 patients with kidney cancer were enrolled. The incidence of VTE/AT during follow-up (median 13 months) was 5.7%. Median overall survival (OS) was relatively lower among subjects with VTE/AT (16 months, 95% CI 0.01-34.2 vs. 27 months, 95% CI 22.6-31.4; p = 0.43). Multivariate analysis failed to reveal predictive variables for developing VTE/ AT. 197 patients with bladder were enrolled. There was a 9.1% incidence rate of VTE/AT during follow-up (median 8 months). Median OS was somewhat higher in patients with VTE/AT (28 months, 95% CI 18.4-37.6 vs 25 months, 95% CI 20.7-29.3; p = 0.821). Serum albumin levels < 3.5 g/dl were predictive of VTE/ AT (p < 0.05). Conclusions: There appears to be no association between developing VTE/AT and ICI use in patients with renal or bladder cancer. Serum albumin levels are a predictive factor in individuals with bladder cancer.

Similares en LA Referencia